Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 4/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17708695 | 1.00 | ALDH1A1 (0.43) | ALDH1A1MEN1KMT2ATDP1MAOB | |
| SCHEMBL17709146 | 0.84 | CYP19A1 (0.55) | MAOBCYP19A1CYP3A4 | |
| SCHEMBL10808822 | 0.80 | ALDH1A1 (0.47) | ALDH1A1MEN1KMT2ATDP1CTDSP1 | |
| SCHEMBL7313853 | 0.73 | CYP4F2 (0.60) | ALDH1A1MEN1KMT2ATDP1PPARG | |
| SCHEMBL7313848 | 0.73 | CYP4F2 (0.60) | ALDH1A1MEN1KMT2ATDP1PPARG | |
| SCHEMBL7313860 | 0.73 | CYP4F2 (0.60) | ALDH1A1MEN1KMT2ATDP1PPARG | |
| SCHEMBL3358045 | 0.72 | ALDH1A1 (0.45) | ALDH1A1MEN1KMT2ATDP1MAPT | |
| SCHEMBL17708758 | 0.72 | CYP19A1 (0.55) | MAOBCYP19A1CYP3A4 | |
| SCHEMBL17708757 | 0.72 | CYP19A1 (0.55) | MAOBCYP19A1CYP3A4 | |
| SCHEMBL17708754 | 0.72 | CYP19A1 (0.55) | MAOBCYP19A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3212189-B1 | SUBSTITUTED CHROMANES AND METHOD OF USE | ABBVIE OVERSEAS SÀ RL (LU) | 2020-09-09 | — | — | EP | disclosed |
| US-20190127356-A1 | Substituted Chromanes and Method of Use | ABBVIE OVERSEAS S.Á.R.L. (LU) | 2019-05-02 | — | — | US | disclosed |
| EP-3212189-A1 | SUBSTITUTED CHROMANES AND METHOD OF USE | AbbVie S.À.R.L. (LU) | 2017-09-06 | — | — | EP | disclosed |
| US-20170190693-A1 | SUBSTITUTED CHROMANES AND METHOD OF USE | ABBVIE S À R L (LU) | 2017-07-06 | — | — | US | disclosed |
| US-9642831-B2 | Substituted chromanes and method of use | ABBVIE S.Á.R.L. (LU) | 2017-05-09 | — | — | US | disclosed |
| WO-2016069757-A1 | SUBSTITUTED CHROMANES AND METHOD OF USE | ABBVIE INC. (US) | 2016-05-06 | — | — | WO | disclosed |
| US-20160120841-A1 | SUBSTITUTED CHROMANES AND METHOD OF USE | ABBVIE GLOBAL LIMITED (BM) | 2016-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190693-A1 | SUBSTITUTED CHROMANES AND METHOD OF USE | CFTR, CHRM3, CHRM2 | ALDH1A1 3588/4885MEN1 1408/4885KMT2A 4725/4885 |
| US-20160120841-A1 | SUBSTITUTED CHROMANES AND METHOD OF USE | CFTR, CHRM3, CHRM2 | ALDH1A1 3588/4885MEN1 1408/4885KMT2A 4725/4885 |
| US-20190127356-A1 | Substituted Chromanes and Method of Use | CFTR, CHRM3, CHRM2 | ALDH1A1 3588/4885MEN1 1408/4885KMT2A 4725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.